{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:48Z","timestamp":1786979988403,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271977"],"award-info":[{"award-number":["82271977"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260339"],"award-info":[{"award-number":["82260339"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Science and Technology Project of Hainan Province","award":["ZDYF2023SHFZ096"],"award-info":[{"award-number":["ZDYF2023SHFZ096"]}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hainan Province","doi-asserted-by":"publisher","award":["824QN372"],"award-info":[{"award-number":["824QN372"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hainan Academician Innovation Platform Fund"},{"name":"Hainan Province Clinical Medical Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-11433-3","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T13:20:51Z","timestamp":1739539251000},"page":"5135-5145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicting progression-free survival using dynamic contrast-enhanced imaging-based radiomics in advanced nasopharyngeal carcinoma patients treated with nimotuzumab"],"prefix":"10.1007","volume":"35","author":[{"given":"Xin","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-zhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-hao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9129-7895","authenticated-orcid":false,"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"11433_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"11433_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"11433_CR3","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.30198","volume":"122","author":"JJ Pan","year":"2016","unstructured":"Pan JJ, Ng WT, Zong JF et al (2016) Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 122:3307\u20133315. https:\/\/doi.org\/10.1002\/cncr.30198","journal-title":"Cancer"},{"key":"11433_CR4","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.21.02449","volume":"40","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Chen L, Hu GQ et al (2022) Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial. J Clin Oncol 40:2420\u20132425. https:\/\/doi.org\/10.1200\/JCO.21.02449","journal-title":"J Clin Oncol"},{"key":"11433_CR5","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.7150\/thno.19388","volume":"7","author":"R You","year":"2017","unstructured":"You R, Hua YJ, Liu YP et al (2017) Concurrent chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. Theranostics 7:2314\u20132324. https:\/\/doi.org\/10.7150\/thno.19388","journal-title":"Theranostics"},{"key":"11433_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2003.08.034","volume":"59","author":"DT Chua","year":"2004","unstructured":"Chua DT, Nicholls JM, Sham JS, Au GK (2004) Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 59:11\u201320. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.08.034","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11433_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10555-017-9693-8","volume":"36","author":"MJ Xu","year":"2017","unstructured":"Xu MJ, Johnson DE, Grandis JR (2017) EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev 36:463\u2013473. https:\/\/doi.org\/10.1007\/s10555-017-9687-8","journal-title":"Cancer Metastasis Rev"},{"key":"11433_CR8","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/hed.10314","volume":"25","author":"BB Ma","year":"2003","unstructured":"Ma BB, Poon TC, To KF et al (2003) Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma\u2014a prospective study. Head Neck 25:864\u2013872. https:\/\/doi.org\/10.1002\/hed.10314","journal-title":"Head Neck"},{"key":"11433_CR9","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/hed.23095","volume":"35","author":"J Pan","year":"2013","unstructured":"Pan J, Tang T, Xu L et al (2013) Prognostic significance of expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma. Head Neck 35:1238\u20131247. https:\/\/doi.org\/10.1002\/hed.23095","journal-title":"Head Neck"},{"key":"11433_CR10","doi-asserted-by":"publisher","first-page":"697369","DOI":"10.3389\/fonc.2021.697369","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Liang R, Lai L, Chen K, Zhu X (2021) Prognostic role of EGFR\/p-EGFR in patients with nasopharyngeal carcinoma: a meta-analysis. Front Oncol 11:697369. https:\/\/doi.org\/10.3389\/fonc.2021.697369","journal-title":"Front Oncol"},{"key":"11433_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2147\/OTT.S80398","volume":"8","author":"K Teng","year":"2015","unstructured":"Teng K, Zhang Y, Hu X, Ding Y, Gong R, Liu L (2015) Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair. Onco Targets Ther 8:809\u2013818. https:\/\/doi.org\/10.2147\/OTT.S80398","journal-title":"Onco Targets Ther"},{"key":"11433_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.oraloncology.2018.03.017","volume":"80","author":"M Lin","year":"2018","unstructured":"Lin M, You R, Liu YP et al (2018) Beneficial effects of anti-EGFR agents, cetuximab or nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma. Oral Oncol 80:1\u20138. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.03.017","journal-title":"Oral Oncol"},{"key":"11433_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/coa.13369","volume":"44","author":"L Mao","year":"2019","unstructured":"Mao L, Tan J, Wang F et al (2019) Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression. Clin Otolaryngol 44:572\u2013580. https:\/\/doi.org\/10.1111\/coa.13369","journal-title":"Clin Otolaryngol"},{"key":"11433_CR14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/ijc.30816","volume":"141","author":"R You","year":"2017","unstructured":"You R, Sun R, Hua YJ et al (2017) Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma. Int J Cancer 141:1265\u20131276. https:\/\/doi.org\/10.1002\/ijc.30816","journal-title":"Int J Cancer"},{"key":"11433_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6412-4","volume":"19","author":"Y Lu","year":"2019","unstructured":"Lu Y, Chen D, Liang J et al (2019) Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study. BMC Cancer 19:1262. https:\/\/doi.org\/10.1186\/s12885-019-6412-4","journal-title":"BMC Cancer"},{"key":"11433_CR16","doi-asserted-by":"publisher","unstructured":"Xiao B, Wang P, Zhao Y, Liu Y, Ye Z (2020) Nasopharyngeal carcinoma perfusion MRI: comparison of arterial spin labeling and dynamic contrast-enhanced MRI. Medicine (Baltimore). https:\/\/doi.org\/10.1097\/MD.0000000000020503","DOI":"10.1097\/MD.0000000000020503"},{"key":"11433_CR17","first-page":"171","volume":"5","author":"C Wang","year":"2018","unstructured":"Wang C, Sun W, Kirkpatrick J, Chang Z, Yin FF (2018) Assessment of concurrent stereotactic radiosurgery and bevacizumab treatment of recurrent malignant gliomas using multi-modality MRI imaging and radiomics analysis. J Radiosurg SBRT 5:171\u2013181","journal-title":"J Radiosurg SBRT"},{"key":"11433_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630780","volume":"11","author":"S Montemezzi","year":"2021","unstructured":"Montemezzi S, Benetti G, Bisighin MV et al (2021) 3T DCE-MRI radiomics improves predictive models of complete response to neoadjuvant chemotherapy in breast cancer. Front Oncol 11:630780. https:\/\/doi.org\/10.3389\/fonc.2021.630780","journal-title":"Front Oncol"},{"key":"11433_CR19","doi-asserted-by":"publisher","first-page":"911.e1","DOI":"10.1016\/j.crad.2018.05.018","volume":"73","author":"A Palmisano","year":"2018","unstructured":"Palmisano A, Esposito A, Rancoita P et al (2018) Could perfusion heterogeneity at dynamic contrast-enhanced MRI be used to predict rectal cancer sensitivity to chemoradiotherapy. Clin Radiol 73:911.e1\u2013911.e7. https:\/\/doi.org\/10.1016\/j.crad.2018.05.018","journal-title":"Clin Radiol"},{"key":"11433_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.955866","volume":"12","author":"WZ Li","year":"2022","unstructured":"Li WZ, Wu G, Li TS et al (2022) Dynamic contrast-enhanced magnetic resonance imaging-based radiomics for the prediction of progression-free survival in advanced nasopharyngeal carcinoma. Front Oncol 12:955866. https:\/\/doi.org\/10.3389\/fonc.2022.955866","journal-title":"Front Oncol"},{"key":"11433_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.radonc.2021.09.009","volume":"164","author":"W Huang","year":"2021","unstructured":"Huang W, Zhang Q, Wu G et al (2021) DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1\u03b1, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients. Radiother Oncol 164:146\u2013154. https:\/\/doi.org\/10.1016\/j.radonc.2021.09.009","journal-title":"Radiother Oncol"},{"key":"11433_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3322\/caac.21389","volume":"67","author":"WM Lydiatt","year":"2017","unstructured":"Lydiatt WM, Patel SG, O\u2019Sullivan B et al (2017) Head and neck cancers\u2014major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 67:122\u2013137. https:\/\/doi.org\/10.3322\/caac.21389","journal-title":"CA Cancer J Clin"},{"key":"11433_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.6004\/jnccn.2022.0011","volume":"20","author":"JJ Caudell","year":"2022","unstructured":"Caudell JJ, Gillison ML, Maghami E et al (2022) NCCN Guidelines\u00ae Insights: head and neck cancers, version 1.2022. J Natl Compr Canc Netw 20:224\u2013234. https:\/\/doi.org\/10.6004\/jnccn.2022.0011","journal-title":"J Natl Compr Canc Netw"},{"key":"11433_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4161\/cbt.9.5.10725","volume":"9","author":"MO Rodr\u00edguez","year":"2010","unstructured":"Rodr\u00edguez MO, Rivero TC, del Castillo Bahi R et al (2010) Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 9:343\u2013349. https:\/\/doi.org\/10.4161\/cbt.9.5.10725","journal-title":"Cancer Biol Ther"},{"key":"11433_CR25","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/1078-0432.CCR-09-2836","volume":"16","author":"F Rojo","year":"2010","unstructured":"Rojo F, Gracias E, Villena N et al (2010) Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 16:2474\u20132482. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2836","journal-title":"Clin Cancer Res"},{"key":"11433_CR26","doi-asserted-by":"publisher","first-page":"600","DOI":"10.4161\/cbt.13.8.19916","volume":"13","author":"M Ramos-Suzarte","year":"2012","unstructured":"Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG et al (2012) Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 13:600\u2013605. https:\/\/doi.org\/10.4161\/cbt.13.8.19916","journal-title":"Cancer Biol Ther"},{"key":"11433_CR27","doi-asserted-by":"publisher","first-page":"18674","DOI":"10.18632\/oncotarget.4517","volume":"6","author":"CY Wang","year":"2015","unstructured":"Wang CY, Deng JY, Cai XW et al (2015) High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis. Oncotarget 6:18674\u201318682. https:\/\/doi.org\/10.18632\/oncotarget.4517","journal-title":"Oncotarget"},{"key":"11433_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/1568009616666161108165518","volume":"17","author":"C Zhou","year":"2017","unstructured":"Zhou C, Zhu L, Ji J et al (2017) EGFR high expression, but not KRAS status, predicts sensitivity of pancreatic cancer cells to nimotuzumab treatment in vivo. Curr Cancer Drug Targets 17:89\u201397. https:\/\/doi.org\/10.2174\/1568009616666161108165518","journal-title":"Curr Cancer Drug Targets"},{"key":"11433_CR29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/cam4.617","volume":"5","author":"Y Nitta","year":"2016","unstructured":"Nitta Y, Shimizu S, Shishido-Hara Y, Suzuki K, Shiokawa Y, Nagane M (2016) Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. Cancer Med 5:486\u2013499. https:\/\/doi.org\/10.1002\/cam4.617","journal-title":"Cancer Med"},{"key":"11433_CR30","doi-asserted-by":"publisher","unstructured":"Yuan-Yuan Q, Song-Liu H, Xiang-Ying X et al (2013) Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0070727","DOI":"10.1371\/journal.pone.0070727"},{"key":"11433_CR31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.radonc.2009.03.009","volume":"92","author":"N Zhang","year":"2009","unstructured":"Zhang N, Erjala K, Kulmala J et al (2009) Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol 92:388\u2013392. https:\/\/doi.org\/10.1016\/j.radonc.2009.04.019","journal-title":"Radiother Oncol"},{"key":"11433_CR32","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1158\/0008-5472.CAN-08-4817","volume":"69","author":"A Talavera","year":"2009","unstructured":"Talavera A, Friemann R, G\u00f3mez-Puerta S et al (2009) Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 69:5851\u20135859. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4817","journal-title":"Cancer Res"},{"key":"11433_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.mri.2021.08.008","volume":"83","author":"A Mui","year":"2021","unstructured":"Mui A, Lee A, Lee V et al (2021) Prognostic and therapeutic evaluation of nasopharyngeal carcinoma by dynamic contrast-enhanced (DCE), diffusion-weighted (DW) magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). Magn Reson Imaging 83:50\u201356. https:\/\/doi.org\/10.1016\/j.mri.2021.07.003","journal-title":"Magn Reson Imaging"},{"key":"11433_CR34","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/jmri.24747","volume":"41","author":"D Zheng","year":"2015","unstructured":"Zheng D, Ren W, Qin Y, Wang P, Li Y (2015) Early response to chemoradiotherapy for nasopharyngeal carcinoma treatment: value of dynamic contrast-enhanced 3.0 T MRI. J Magn Reson Imaging 41:1528\u20131540. https:\/\/doi.org\/10.1002\/jmri.24747","journal-title":"J Magn Reson Imaging"},{"key":"11433_CR35","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.acra.2019.02.013","volume":"26","author":"Y Qin","year":"2019","unstructured":"Qin Y, Yu X, Hou J et al (2019) Prognostic value of the pretreatment primary lesion quantitative dynamic contrast-enhanced magnetic resonance imaging for nasopharyngeal carcinoma. Acad Radiol 26:1473\u20131482. https:\/\/doi.org\/10.1016\/j.acra.2019.01.021","journal-title":"Acad Radiol"},{"key":"11433_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s42492-023-00111-4","volume":"6","author":"H Li","year":"2023","unstructured":"Li H, Huang W, Wang S et al (2023) Comprehensive integrated analysis of MR and DCE-MR radiomics models for prognostic prediction in nasopharyngeal carcinoma. Vis Comput Ind Biomed Art 6:23. https:\/\/doi.org\/10.1186\/s42492-023-00149-0","journal-title":"Vis Comput Ind Biomed Art"},{"key":"11433_CR37","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1158\/1078-0432.CCR-16-3114","volume":"23","author":"B Zhang","year":"2017","unstructured":"Zhang B, Tian J, Dong D et al (2017) Radiomics features of multiparametric MRI as novel prognostic factors in advanced nasopharyngeal carcinoma. Clin Cancer Res 23:4259\u20134269. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2910","journal-title":"Clin Cancer Res"},{"key":"11433_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.oraloncology.2019.09.020","volume":"98","author":"K Yang","year":"2019","unstructured":"Yang K, Tian J, Zhang B et al (2019) A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 98:85\u201391. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.09.022","journal-title":"Oral Oncol"},{"key":"11433_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.radonc.2022.05.002","volume":"171","author":"H Shen","year":"2022","unstructured":"Shen H, Yin J, Niu R et al (2022) MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a multicenter study. Radiother Oncol 171:107\u2013113. https:\/\/doi.org\/10.1016\/j.radonc.2022.04.017","journal-title":"Radiother Oncol"}],"updated-by":[{"DOI":"10.1007\/s00330-025-11530-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000}}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11433-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:16:36Z","timestamp":1751544996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11433-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["11433"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11433-3","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the original article sub-captions in Figure 4 were labelled incorrectly. In Figure 4, the second labels \u2018<b>A<\/b>\u2019 and \u2018<b>B<\/b>\u2019 should have been \u2018<b>C<\/b>\u2019 and \u2018<b>D<\/b>\u2019.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00330-025-11530-3","URL":"https:\/\/doi.org\/10.1007\/s00330-025-11530-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Feng Chen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study subjects or cohorts were not reported.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}